The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday. The drug, known scientifically as ...

The European Commission has formally approved a twice-yearly injection to prevent HIV, clearing the way for the jab to be ...

AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major ...

The European Commission has granted marketing authorization for Yeytuo (lenacapavir)—Gilead Sciences Inc.’s twice-yearly ...

Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.

Here are some other results for Marion-area boys fall sports teams: ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

In this article, we will take a detailed look at the Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings.

North Union notched a school record for goals scored in a girls soccer game as the Lady Cats defeated Pleasant 19-1 on Saturday at NU. Kale Keigley had five goals for North Union (3-0-1), tying a ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...